The discovery of epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) was a breakthrough that established a paradigm of precision medicine for the treatment of EGFR-mutant NSCLC over the past few decades. Here, EGFR is linked to non-small cell lung carcinoma.